{"id":"NCT04146363","sponsor":"Eli Lilly and Company","briefTitle":"Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)","officialTitle":"A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-24","primaryCompletion":"2021-06-21","completion":"2022-05-03","firstPosted":"2019-10-31","resultsPosted":"2022-08-29","lastUpdate":"2022-11-30"},"enrollment":424,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"BIOLOGICAL","name":"Lebrikizumab","otherNames":["LY3650150","DRM06"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Lebrikizumab 250 Q2W","type":"EXPERIMENTAL"},{"label":"Lebrikizumab 250 Q4W","type":"EXPERIMENTAL"},{"label":"Escape Arm (Lebrikizumab Q2W)","type":"EXPERIMENTAL"}],"summary":"This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.","primaryOutcome":{"measure":"Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction â‰¥2 Points From Baseline to Week 16","timeFrame":"Baseline to Week 16","effectByArm":[{"arm":"Placebo","deltaMin":12.7,"sd":null},{"arm":"Lebrikizumab Q2W","deltaMin":43.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.000001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":94,"countries":["United States","Australia","Canada","Estonia","France","Latvia","Lithuania","Poland","South Korea","Spain"]},"refs":{"pmids":["40663228","39249591","39123054","39002092","38922484","38700646","38679419","36994947","36920778"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/6duv4kD1B48RPwp63igF1U"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":141},"commonTop":["Dermatitis atopic","Conjunctivitis","Nasopharyngitis","Covid-19","Conjunctivitis allergic"]}}